Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126

Andrew Eppstein, John A. Sandoval, Patrick J. Klein, Heather A. Woodruff, Jay L. Grosfeld, Robert J. Hickey, Linda H. Malkas, C. Schmidt

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Neuroblastoma tumors are comprised of neuroblastic (N), substrate-adherent (S), and intermediate (I) cells. Because cell growth and differentiation often involve p44/p42 mitogen-activated protein kinase (MAPK) pathway signaling, we explored MAPK signaling and growth response in three NB cell types after MAPK kinase (MEK) inhibition to evaluate the feasibility of MAPK-targeted treatment strategies. Methods: Three human NB cell cultures, SH-SY5Y (N-type), BE(2)-C (I-type), and SK-N-AS (S-type), were treated in monolayer cultures with increasing concentrations of the MEK inhibitor U0126. MAPK pathway intermediates MEK and ERK, their activated (phosphorylated) forms p-MEK and p-ERK, and p53 expression were assessed by Western blot at 1 and 24 hours. At 72 hours, cell counts determined growth inhibition and DNA fragmentation ELISA assessed apoptosis. Results: Among all three lines, total ERK and MEK expression were unaffected by U0126. However, constitutive total ERK and p53 expression were significantly greater in BE(2)-C (I-type) cells than in SH-SY5Y (N-type) and SK-N-AS (S-type). Active ERK (p-ERK) levels decreased in dose response to U0126 at 1 and 24 hours in all lines. Conversely, p-MEK levels increased with increasing U0126 concentrations at 1 hour in SH-SY5Y (N-type) and at 24 hours in all lines. BE(2)-C (I-type) cell counts decreased in concentration-dependent fashion with U0126, whereas SH-SY5Y (N-type) and SK-N-AS (S-type) showed a biphasic response with increased cell counts at 1 μmol/L U0126 and slightly decreased cell counts at 10 μmol/L U0126. Conclusion: This study demonstrates that BE(2)-C (I-type) cells exhibit greater constitutive total ERK and p53 expression than SH-SY5Y (N-type) and SK-N-AS (S-type). Although all three lines exhibit p-ERK decreases with MEK inhibition, only BE(2)-C (I-type) cells significantly decrease their proliferation with U0126 treatment. Although MEK inhibition holds promise in targeting I-type NB cells, successfully treating this heterogeneous tumor may require combining agents against N- and S-type cells.

Original languageEnglish
Pages (from-to)252-259
Number of pages8
JournalJournal of Pediatric Surgery
Volume41
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Mitogen-Activated Protein Kinases
Neuroblastoma
Cell Count
Therapeutics
Growth
U 0126
MAP Kinase Signaling System
Mitogen-Activated Protein Kinase 1
DNA Fragmentation
Cell Differentiation
Neoplasms
Cell Culture Techniques
Western Blotting
Enzyme-Linked Immunosorbent Assay
Apoptosis

Keywords

  • MAPK resistance
  • Mitogen-activated protein kinase (MAPK)
  • N-type, S-type, I-type
  • Neuroblastoma

ASJC Scopus subject areas

  • Surgery

Cite this

Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. / Eppstein, Andrew; Sandoval, John A.; Klein, Patrick J.; Woodruff, Heather A.; Grosfeld, Jay L.; Hickey, Robert J.; Malkas, Linda H.; Schmidt, C.

In: Journal of Pediatric Surgery, Vol. 41, No. 1, 01.2006, p. 252-259.

Research output: Contribution to journalArticle

Eppstein, Andrew ; Sandoval, John A. ; Klein, Patrick J. ; Woodruff, Heather A. ; Grosfeld, Jay L. ; Hickey, Robert J. ; Malkas, Linda H. ; Schmidt, C. / Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. In: Journal of Pediatric Surgery. 2006 ; Vol. 41, No. 1. pp. 252-259.
@article{80322ed4f8b949c9a1ac89280d64ec3c,
title = "Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126",
abstract = "Purpose: Neuroblastoma tumors are comprised of neuroblastic (N), substrate-adherent (S), and intermediate (I) cells. Because cell growth and differentiation often involve p44/p42 mitogen-activated protein kinase (MAPK) pathway signaling, we explored MAPK signaling and growth response in three NB cell types after MAPK kinase (MEK) inhibition to evaluate the feasibility of MAPK-targeted treatment strategies. Methods: Three human NB cell cultures, SH-SY5Y (N-type), BE(2)-C (I-type), and SK-N-AS (S-type), were treated in monolayer cultures with increasing concentrations of the MEK inhibitor U0126. MAPK pathway intermediates MEK and ERK, their activated (phosphorylated) forms p-MEK and p-ERK, and p53 expression were assessed by Western blot at 1 and 24 hours. At 72 hours, cell counts determined growth inhibition and DNA fragmentation ELISA assessed apoptosis. Results: Among all three lines, total ERK and MEK expression were unaffected by U0126. However, constitutive total ERK and p53 expression were significantly greater in BE(2)-C (I-type) cells than in SH-SY5Y (N-type) and SK-N-AS (S-type). Active ERK (p-ERK) levels decreased in dose response to U0126 at 1 and 24 hours in all lines. Conversely, p-MEK levels increased with increasing U0126 concentrations at 1 hour in SH-SY5Y (N-type) and at 24 hours in all lines. BE(2)-C (I-type) cell counts decreased in concentration-dependent fashion with U0126, whereas SH-SY5Y (N-type) and SK-N-AS (S-type) showed a biphasic response with increased cell counts at 1 μmol/L U0126 and slightly decreased cell counts at 10 μmol/L U0126. Conclusion: This study demonstrates that BE(2)-C (I-type) cells exhibit greater constitutive total ERK and p53 expression than SH-SY5Y (N-type) and SK-N-AS (S-type). Although all three lines exhibit p-ERK decreases with MEK inhibition, only BE(2)-C (I-type) cells significantly decrease their proliferation with U0126 treatment. Although MEK inhibition holds promise in targeting I-type NB cells, successfully treating this heterogeneous tumor may require combining agents against N- and S-type cells.",
keywords = "MAPK resistance, Mitogen-activated protein kinase (MAPK), N-type, S-type, I-type, Neuroblastoma",
author = "Andrew Eppstein and Sandoval, {John A.} and Klein, {Patrick J.} and Woodruff, {Heather A.} and Grosfeld, {Jay L.} and Hickey, {Robert J.} and Malkas, {Linda H.} and C. Schmidt",
year = "2006",
month = "1",
doi = "10.1016/j.jpedsurg.2005.10.047",
language = "English",
volume = "41",
pages = "252--259",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126

AU - Eppstein, Andrew

AU - Sandoval, John A.

AU - Klein, Patrick J.

AU - Woodruff, Heather A.

AU - Grosfeld, Jay L.

AU - Hickey, Robert J.

AU - Malkas, Linda H.

AU - Schmidt, C.

PY - 2006/1

Y1 - 2006/1

N2 - Purpose: Neuroblastoma tumors are comprised of neuroblastic (N), substrate-adherent (S), and intermediate (I) cells. Because cell growth and differentiation often involve p44/p42 mitogen-activated protein kinase (MAPK) pathway signaling, we explored MAPK signaling and growth response in three NB cell types after MAPK kinase (MEK) inhibition to evaluate the feasibility of MAPK-targeted treatment strategies. Methods: Three human NB cell cultures, SH-SY5Y (N-type), BE(2)-C (I-type), and SK-N-AS (S-type), were treated in monolayer cultures with increasing concentrations of the MEK inhibitor U0126. MAPK pathway intermediates MEK and ERK, their activated (phosphorylated) forms p-MEK and p-ERK, and p53 expression were assessed by Western blot at 1 and 24 hours. At 72 hours, cell counts determined growth inhibition and DNA fragmentation ELISA assessed apoptosis. Results: Among all three lines, total ERK and MEK expression were unaffected by U0126. However, constitutive total ERK and p53 expression were significantly greater in BE(2)-C (I-type) cells than in SH-SY5Y (N-type) and SK-N-AS (S-type). Active ERK (p-ERK) levels decreased in dose response to U0126 at 1 and 24 hours in all lines. Conversely, p-MEK levels increased with increasing U0126 concentrations at 1 hour in SH-SY5Y (N-type) and at 24 hours in all lines. BE(2)-C (I-type) cell counts decreased in concentration-dependent fashion with U0126, whereas SH-SY5Y (N-type) and SK-N-AS (S-type) showed a biphasic response with increased cell counts at 1 μmol/L U0126 and slightly decreased cell counts at 10 μmol/L U0126. Conclusion: This study demonstrates that BE(2)-C (I-type) cells exhibit greater constitutive total ERK and p53 expression than SH-SY5Y (N-type) and SK-N-AS (S-type). Although all three lines exhibit p-ERK decreases with MEK inhibition, only BE(2)-C (I-type) cells significantly decrease their proliferation with U0126 treatment. Although MEK inhibition holds promise in targeting I-type NB cells, successfully treating this heterogeneous tumor may require combining agents against N- and S-type cells.

AB - Purpose: Neuroblastoma tumors are comprised of neuroblastic (N), substrate-adherent (S), and intermediate (I) cells. Because cell growth and differentiation often involve p44/p42 mitogen-activated protein kinase (MAPK) pathway signaling, we explored MAPK signaling and growth response in three NB cell types after MAPK kinase (MEK) inhibition to evaluate the feasibility of MAPK-targeted treatment strategies. Methods: Three human NB cell cultures, SH-SY5Y (N-type), BE(2)-C (I-type), and SK-N-AS (S-type), were treated in monolayer cultures with increasing concentrations of the MEK inhibitor U0126. MAPK pathway intermediates MEK and ERK, their activated (phosphorylated) forms p-MEK and p-ERK, and p53 expression were assessed by Western blot at 1 and 24 hours. At 72 hours, cell counts determined growth inhibition and DNA fragmentation ELISA assessed apoptosis. Results: Among all three lines, total ERK and MEK expression were unaffected by U0126. However, constitutive total ERK and p53 expression were significantly greater in BE(2)-C (I-type) cells than in SH-SY5Y (N-type) and SK-N-AS (S-type). Active ERK (p-ERK) levels decreased in dose response to U0126 at 1 and 24 hours in all lines. Conversely, p-MEK levels increased with increasing U0126 concentrations at 1 hour in SH-SY5Y (N-type) and at 24 hours in all lines. BE(2)-C (I-type) cell counts decreased in concentration-dependent fashion with U0126, whereas SH-SY5Y (N-type) and SK-N-AS (S-type) showed a biphasic response with increased cell counts at 1 μmol/L U0126 and slightly decreased cell counts at 10 μmol/L U0126. Conclusion: This study demonstrates that BE(2)-C (I-type) cells exhibit greater constitutive total ERK and p53 expression than SH-SY5Y (N-type) and SK-N-AS (S-type). Although all three lines exhibit p-ERK decreases with MEK inhibition, only BE(2)-C (I-type) cells significantly decrease their proliferation with U0126 treatment. Although MEK inhibition holds promise in targeting I-type NB cells, successfully treating this heterogeneous tumor may require combining agents against N- and S-type cells.

KW - MAPK resistance

KW - Mitogen-activated protein kinase (MAPK)

KW - N-type, S-type, I-type

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=30344442477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344442477&partnerID=8YFLogxK

U2 - 10.1016/j.jpedsurg.2005.10.047

DO - 10.1016/j.jpedsurg.2005.10.047

M3 - Article

C2 - 16410143

AN - SCOPUS:30344442477

VL - 41

SP - 252

EP - 259

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 1

ER -